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ABSTRACT Macrophage migration inhibitory factor
(MIF) affects inflammation, glucose homeostasis, and
cellular proliferation in mammals. Previously, we
found that MIF was significantly elevated in multiple
long-lived mouse models, including calorie restriction
(CR), which led us to hypothesize that MIF might be
important in the control of mammalian life span and be
necessary for the life-extending effects of CR. To test
this hypothesis, we examined the life span of mice with
a targeted deletion of the Mif gene on a segregating
B6  129/Sv background (MIF-KO) under ad libitum
(AL) feeding and CR conditions. Control mice were
generated by mating C57BL/6J females with 129/SvJ
males to make an F1 hybrid, and crossing F1 males to
F1 females to produce segregating F2 mice homozy-
gous for the normal MIF allele. Not only did MIF-KO
mice show a life span extension in response to CR, they
were, unexpectedly, longer lived than controls under
standard AL conditions. MIF-KO mice were signifi-
cantly protected against lethal hemangiosarcoma, but
more likely than controls to die of disseminated amy-
loid, an age-related inflammatory syndrome. Overall,
these data refute the suggestion that MIF is required
for the CR effect on life span, but raise the possibility
that MIF may limit life span in normal mice.—Harper,
J. M., Wilkinson, J. E., Miller, R. A. Macrophage
migration inhibitory factor-knockout mice are long
lived and respond to caloric restriction. FASEB J. 24,
2436–2442 (2010). www.fasebj.org
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Macrophage migration inhibitory factor (MIF) was
first described as a T-cell-derived cytokine that could
inhibit the migration of macrophages in vitro (1).
Further work showed that MIF is expressed in many
other cell types, most notably the pancreas and pitu-
itary gland. MIF is unusual for a cytokine, in that it is
constitutively produced and stored in intracellular
pools, obviating the need for de novo synthesis prior to
its release (2, 3). MIF is now considered to be an
important component of the innate immune response,
opposing the anti-inflammatory effects of glucocor-
tioids on a host of cell/tissue types at both the local and
systemic level (4). Pharmacological inhibition of the
proinflammatory effects of MIF has shown promise as a
clinical approach to protecting patients from poten-
tially lethal septic shock and other inflammatory con-
ditions (5).
In addition to its contribution to inflammation, there
is a growing body of evidence to suggest that MIF is an
important regulator of energy metabolism via its neu-
roendocrine effects on insulin signaling pathways in the
pancreas, muscle, and adipocytes (6). More recently,
MIF has also been implicated as a contributor to tumor
growth and progression (7) through its effects on
tumor vascularization and alteration of apoptotic sig-
naling pathways (8, 9). Approaches that diminish MIF
function are being tested to see whether they might
have therapeutic value to treat a variety of cancers
(10–13).
An early study showed that local production of MIF
by stimulated immune cells was reduced by aging in
guinea pigs (14, 15), but there is no significant change
in serum MIF level during healthy aging in humans (16,
17). Studies on MIF effects in invertebrate models of
delayed aging are now also in progress, in part because
MIF is a mediator of hypoxia inducible factor-1 (HIF-
1) activity, a regulator of cellular senescence in vitro
(18, 19), which can also modulate life span in inverte-
brates (20, 21).
In our own work, an unbiased study of gene expres-
sion profiles showed that the basal expression of MIF
mRNA was significantly elevated in the liver of long-
lived Snell dwarf and growth hormone receptor-
knockout (GHR-KO) mice relative to their normal-
lived counterparts (22). Moreover, we found that mice
maintained on either of two antiaging diets, i.e., calorie
restriction (CR) or a diet low in the essential amino
acid methionine (Meth-R), also had significantly ele-
vated levels of MIF mRNA in the liver (22, 23). In
addition, MIF mRNA is significantly elevated in the
liver of long-lived Idaho-derived wild mice compared to
a genetically heterogeneous population of laboratory
mice (unpublished data). The finding that liver MIF
expression is significantly elevated by CR has recently
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been confirmed by an independent group, who found
increased MIF expression in heart and skeletal muscle
as well (24). Taken together, these data led us to
hypothesize that MIF might be required for the life-
span-extending effects of CR. To test this hypothesis, we
examined the life span of mice with a targeted disrup-
tion of the Mif gene (MIF-KO) (25) under both ad
libitum (AL) feeding and CR conditions.
MATERIALS AND METHODS
MIF-KO mice were produced as described previously (25, 26)
and kindly provided to us by Dr. Abhay Satoskar (Ohio State
University, Columbus, OH, USA) as homozygotes on a segre-
gating (C57BL/6J129/SvJae) background. Control mice
were generated at Michigan by mating C57BL/6J females
with 129/SvJ males to make an F1 hybrid, and crossing F1
males to F1 females to produce segregating F2 mice, homozy-
gous for the normal MIF allele. We will refer to these control
mice as (B6129)F2. Only female mice were used for this
study and were housed at a density of 4 mice/cage. Mice were
maintained using standard specific pathogen-free (SPF) hus-
bandry techniques; sentinel animals were exposed to spent
bedding on a quarterly basis to check for possible pathogen
infection, and all such tests came up negative over the course
of the study. At the age of 6 wk, mice of each genotype in the
CR groups were given an amount of Purina Lab Diet 5001
(PMI Nutrition International, St. Louis, MO, USA) equal to
90% of the amount consumed by mice in the respective AL
group for 2 wk. They were then shifted to 75% food availabil-
ity for 2 wk and then shifted to 60% food intake for the
remainder of the experiment. The CR mice of either geno-
type in this study did not receive any vitamin or mineral
supplements. Previous studies have demonstrated a robust CR
effect on life span using this protocol (27). Mice were
provided with tap water ad libitum. A total of 24, 24, 39, and 39
mice were used for the control AL, control CR, MIFKO AL,
and MIFKO CR groups, respectively.
Mice were weighed at 1, 2, 3, 6, 12, 18, and 24 mo of age
and were inspected daily, and the date of death was recorded
for each animal. Mice were euthanized if they were found to
be so severely ill that in the opinion of an experienced
caretaker they were unlikely to survive more than another few
days. For each group, slightly more than half of the mice were
found dead (14/24, 15/24, 21/39, and 26/39 for control AL,
control CR, MIFKO AL, and MIFKO CR mice, respectively)
while the remainder were euthanized when moribund. At the
time of death, the body cavity and the base of the skull were
opened, and the mice were immersed in 10% formalin and
stored for up to 3 yr prior to necropsy. A complete necropsy
was done on each animal. The skin, subcutis, and mammary
glands were examined carefully for inflammatory lesions or
tumors. Sections of kidneys, adrenal glands, liver, spleen,
heart, skeletal muscle, lung ovary, and uterus were embedded
in paraffin, cut, and stained with hematoxylin and eosin
(H&E) for histopathologic examination. In addition, any
grossly detectable lesion was processed for histopathology.
RESULTS
The initial hypothesis was that MIF-KO mice would not
respond to CR. We did not expect to see any difference
in life span between the two stocks fed the AL diet. Both
working hypotheses proved incorrect (Fig. 1). When
fed the AL diet, MIF-KO mice were significantly longer-
lived than their (B6129)F2 controls (log-rank test,
P0.001), and MIF-KO mice exhibited a robust life-
span extension in response to CR (P0.003). As ex-
pected, CR resulted in a significant increase in life span
in the (B6129)F2 controls (P0.001). There was no
significant difference in life span of MIF-KO and
(B6129)F2 mice fed the CR diet (P0.3; Fig. 1).
Median survival in the 24 AL control mice was 774 d
(95% confidence interval, 714–834 d); median survival
in the 39 AL MIF-KO mice was 16% higher (895 d, CI
843–947). Among CR mice, median survival of the 24
controls was 1045 d (CI 960–1130), and was 1064 d (CI
1021–1107) in the 39 CR MIF-KO, an increase of 35 and
19%, respectively, relative to AL mice of the same
genotype. The increase in longevity seen with CR in the
(B6129)F2 control stock is typical of that normally
seen in mice undergoing this degree of CR (28). As a
test of maximum life span, we used the method of
Wang and Allison (29), which applies the Fisher exact
test to the proportion of mice alive in each group at the
age when 90% of the pooled population has died.
Among AL mice, 0/24 of the controls were alive at the
cutoff date (1043 d), compared to 7/39 of the MIF-KO
mice (P0.01). As expected, CR led to a significant
increase in maximum life span among control mice
(0/24 of the AL mice and 5/24 of CR mice were alive
at 1275 d; P0.05). There was a trend toward a CR
effect on maximal longevity even in the long-lived
MIF-KO mice, with 2/39 of the control vs. 6/39 of the
MIF-KO mice still alive at 1178 d, but the effect did not
reach statistical significance in this fairly small study.
Phenotypically, MIF-KO mice appear normal on mul-
tiple genetic backgrounds. Offspring are generated in
the expected 1:2:1 genotypic ratio, and the litter sizes of
heterozygous and homozygous matings are normal. In
addition, gross and histopathological analyses of multi-
ple organs have revealed no abnormalities (25, 30)
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Figure 1. MIF-KO mice are significantly long lived (log-rank,
P0.001) relative to (B6129)F2 control mice, and exhibit a
significant life-span extension in response to CR. Kaplan-
Meier survival curves for each genotype and dietary condi-
tion; each point represents a single mouse.
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except that testes weight is reduced in conjunction with
ultrastructural abnormalities in the acrosome, apical
ectoplasmic specialization and spermatids; both Leydig
and Sertoli cells are normal (31). Moreover, counts of
blood cells have revealed no differences in the ratio of
cell types between genotypes, while flow cytometric
analyses of splenocytes and thymocytes indicated nor-
mal ratios of lymphocyte populations (25, 30). How-
ever, although a difference in body weight had not
previously been reported, we found that MIF-KO mice
were lighter in weight than the control stock for at least
the first 24 mo of life under both AL and CR conditions
(Fig. 2). A repeated-measures ANOVA indicated that
there are significant main effects on body weight for
both genotype (P0.0001) and diet (P0.0001; n12–
35/point dependent on genotype and diet), but the
interaction term was not significant (P0.4), indicating
that each stock responded to the CR diet in a similar
way. Body length was not measured. In addition, pilot
studies conducted in a second, distinct population of 6-
to 12-mo-old (B6129)F2 and MIF-KO mice indicated
there is no difference in serum insulin-like growth
factor-1 (IGF-I), food-deprived glucose, or fecal corti-
costeroid level in control vs. MIF-KO mice under both
the AL and CR feeding regimens (P0.4 for all);
although CR did result in a significant reduction in
glucose and IGF-I level (P0.02) concomitant with an
increase in fecal corticosteroid level (P0.04) as ex-
pected (data not shown).
Necropsies that included histopathological analysis
were conducted on 29 control mice and 49 MIF-KO
mice. Excluding those in which autolysis was too ad-
vanced to allow diagnosis, 26 controls (14 AL and 12
CR) and 45 MIF-KO cases (22 AL and 23 CR) produced
useful findings. The pathologist attempted to assign a
most likely cause of death, i.e., to determine whether
any specific disease or combination of diseases was
sufficiently advanced that it could plausibly have led to
the death of the mouse (for those found dead) or to
the symptoms that led to the decision to euthanize mice
in found to be severely ill. Results are shown in Table 1.
There were no statistically significant effects of the CR
diet on occurrence of any tabulated lesion in both
genotypes, and therefore AL and CR groups were
combined for further analysis. The case was classified as
open (i.e., no disease deemed likely to account for
death) in 2/26 (8%) of control and 8/45 (18%) of
MIF-KO mice; these proportions are not significantly
different. Seven of 45 (16%) of the MIF-KO mice, but
none of the controls, were judged to have died of
amyloidosis (P0.03 by Fischer exact test). All of these
animals had severe amyloidosis of the renal glomeruli,
characterized by the deposition of homogenous, acel-
lular, pink, fibrillar material with expansion and com-
plete destruction of the normal glomeruli. The renal
tubules contained significant amounts of protein, with
secondary degeneration of the tubular epithelium. Two
mice also had amyloid deposition in the adrenal gland,
two in the spleen, and one in the liver (Fig. 3). This
pattern of amyloid deposition is consistent with amyloid
derived from the acute-phase protein serum amyloid A
(SAA) and is commonly associated with an aberrant
immune response (32). In MIF-KO mice, it would be
expected that the lack of MIF leads to an increase in
glucocorticoid-mediated immunosuppression (33) and
increased SAA expression (34).
Hemangiosarcoma was judged to have been the
cause of death in 10/26 (38%) of controls but only
6/45 (13%) of MIF-KO mice (P0.01). MIF is capable
of inducing angiogenesis (35) and the absence of MIF
in the KO mice may result in fewer tumors of endothe-
lial origin. Increased longevity due to dietary restriction
has previously been shown to be associated with a
decreased incidence of hemangiosarcoma in mice (34).
The basis for this difference in both models of in-
creased longevity is unclear.
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Figure 2. MIF-KO mice are significantly smaller than
(B6129)F2 mice. Data represent mean  se body weight as
a function of age in each of the two genotypes under each
dietary condition (n12–35 mice/point dependent on geno-
type and diet).
TABLE 1. Results of histopathology studies
Likely cause of death
Control MIF-KO
AL CR AL CR
Open (no diagnosis reached) 1 1 3 5
Adrenal cancer 1 1
Amyloidosis 2 5
Fibrosarcoma 1
Glomerulonephritis 1
Cardiac failure 1
Hemangiosarcoma 3 7 3 3
Histiocytic sarcoma 1
Hydronephrosis 1
Lymphoma 4 2 5 2
Mammary carcinoma 1 1
Ovarian carcinoma 1
Pancreatic islet cell carcinoma 1
Pneumonia 1 1
Pulmonary carcinoma 2 1 2 4
Uterine carcinoma 1 1 1
Total 14 12 22 23
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The extent of glomerulonephritis was also evaluated on
a scale of 0–4 points and found not to show significant
effects of either genotype or diet, although there was a
trend toward reduced severity in CR mice in both the
control group (from 0.710.19 in AL to 0.290.08 in CR,
given as meanse), and in the MIF-KO mice (from
0.330.07 in AL to 0.250.05 in CR).
DISCUSSION
Our principal finding is that ablation of MIF leads to
increased life span in mice. Our confidence in this
conclusion must be tempered by uncertainty about
possible differences in proportions of background
genes between the MIF-KO mice and the (B6129)F2
mice used as controls. The MIF-KO mice were created
by a cross between a chimera derived from a 129S4/
SvJae mouse (36), and mice of the C57BL/6 strain
(whose substrain is unstated in the original publication
(25). Investigations of immune function in the MIF-KO
mice (37, 38) have typically used F2 hybrids between
C57BL/6 and 129/SvJ as controls, because these F2
mice, like the original MIF-KO mice, are expected to
contain C57BL/6 and 129 genes segregating in equal
proportions. We followed this established strategy in
our own set of experiments. It is possible, however, that
some alleles from either parental stock may have be-
come fixed, and others lost, during the 10 yr over which
the MIF-KO mice have been propagated at Harvard
University, Ohio State University, and now the Univer-
sity of Michigan. Thus, we cannot exclude the possibil-
ity that the differences in life span, weight, and pathol-
ogy we described above might reflect differences at loci
other than MIF, and our conclusions should be consid-
ered tentative until similar work has been done using
littermate controls in a population in which the MIF-KO
allele is segregating.
To the best of our knowledge, this is the first time a
reduction in level of a cytokine has been shown to extend
life span in a mammal. Such a finding, if confirmed,
opens new avenues for investigation in rodents, and,
potentially, in human preventive medicine. Drugs or
antibodies that can reduce serum MIF levels or interfere
with MIF action on one or more of its target cell types
might, in principle, duplicate some of the effects of the
MIF-KO mutation on health and life span. A number of
studies have already indicated the utility of neutralizing
MIF activity through the use of monoclonal antibodies
or small chemical inhibitors (e.g., ISO-1) in the control
of autoimmune and inflammatory disease (5, 39–41)
and as a cancer chemotherapeutic strategy (8, 10).
Our data give only a few, preliminary, hints as to the
pathways by which ablation of MIF extends life span in
these mice. Our evidence that MIF-KO mice show a
further life span extension when treated with CR sug-
gests that the lack of MIF does not completely duplicate
the health benefits of CR. On the other hand, we see no
additive effect, i.e., no evidence that MIF-KO mice fed
CR diets live longer than controls fed CR diets. The
observation that a CR diet extends life span in the Ames
pituitary dwarf (27) has been interpreted as evidence
that the Ames mutation and CR diets extend life span
through mechanisms that are at least partially distinct.
Figure 3. AA-amyloidosis in kidney, spleen, liver, and adrenal gland of MIF-KO mice. A) Kidney: diffuse, severe glomerular
AA-amyloidosis (20). B) Glomerular AA-amyloidosis with expansion and destruction of the glomeruli (40). C) Glomerular
AA-amyloidosis (80). D) Spleen: AA-amyloidosis (40). E) Liver: perivascular AA-amyloidosis (40). F) Adrenal-medullary
amyloidosis (40).
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In contrast, the lack of any CR effect on the life span of
GHR-KO mice has suggested that CR and GHR-KO
mice share closely similar pathways for life-span exten-
sion, arguably based on extreme insulin sensitivity (42,
43). The MIF-KO survival curves (Fig. 1) are an inter-
mediate case, in which CR does extend life span of a
long-lived mutant, but not beyond the extent seen in
CR control mice themselves. Elucidation of the path-
ways by which these diets and mutations postpone
lethal illnesses and the other signs of aging will benefit
from replication studies using a wider range of back-
ground genes and dietary formulations, to test the
robustness of the phenomena, as well as evaluation of
mice in which one of more of the purported response
pathways has been inhibited in specific tissues or at
specific developmental stages.
There is a growing body of evidence linking aberrant
MIF expression to inflammatory disease processes and
tumorigenesis (41, 44), and it is plausible that a loss of
MIF function either delays, or slows, the progression
of age-related inflammatory or neoplastic disease in
MIF-KO mice. For example, MIF has been directly
implicated as a mediator of disease progression and
severity in a number of inflammatory conditions, such
as colitis, atherosclerosis, or pancreatitis (45, 47), while
models of experimental inflammation are suppressed
in MIF-KO mice (45, 48, 49). Interestingly, analyses of
genetic polymorphisms in the Mif gene in human popu-
lations have indicated that genetic variants associated with
a reduction in MIF level and/or activity result in a
corresponding reduction in disease severity (50–52).
With regard to tumorigenesis, elevated MIF has been
linked to an increase in tumor incidence and aggres-
sion in a variety of cancers. The list includes prostate
(53), gastric (54), skin (13, 55), breast (56), bladder
(57), colorectal (58), and nervous system (10) cancers.
Genetic variants that result in differential MIF activity
can significantly alter cancer trajectories (11, 59), pre-
sumably due to an influence of MIF on cell growth and
cell cycle regulatory proteins, such as p53 and Akt, as
well as its proangiogenic effects (60). In this context, it
is noteworthy that the incidence of hemangiosarcoma
was significantly reduced in our MIF-KO mice.
In addition, there is emerging evidence that MIF is an
important mediator of glucose metabolism and diabetes
through its influence on insulin release by pancreatic
islets, and through modulation of glucose uptake and
insulin signaling cascades in target cells (e.g., adipocytes,
myocytes). MIF may also influence immunoinflammatory
responses involved in the pathogenesis of Type 1 diabetes
(6). Although it is still somewhat controversial, MIF defi-
ciency generally appears to be antidiabetic (61–64). For
example, loss of MIF protects diabetes-prone LDL recep-
tor deficient (Ldlr/) mice against the development of
age-related insulin resistance and glucose intolerance,
apparently through a reduction in inflammatory pathways
in white adipose tissue (64). MIF-KO mice are also less
prone to streptozotocin-induced diabetes (63). In hu-
mans, MIF is significantly elevated in diabetics (65), and
chronic elevation of MIF precedes the onset of type 2
diabetes (66). Similarly, there is a clear association be-
tween MIF gene polymorphisms, MIF activity, and diabe-
tes (62, 67) in humans.
Finally, MIF has well-known effects on the hypotha-
lamic-pituitary-adrenal (HPA) axis. It is released in
conjunction with adrenocorticotrophin (ACTH) from
the pituitary gland during times of physiological and
psychological stress (1). On release, MIF acts primarily
as a negative regulator of glucocorticoid (GC) activity,
especially with respect to effects on immune cells (33),
via a reduction in ACTH and GC production and/or
secretion (68, 69). In this context, it is noteworthy that
HPA axis responsiveness to restraint stress can predict
life span in young adult inbred rats (70–72).
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